Equities

Neumora Therapeutics Inc

NMRA:NSQ

Neumora Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.65
  • Today's Change-0.04 / -0.41%
  • Shares traded220.33k
  • 1 Year change-18.98%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.

  • Revenue in USD (TTM)0.00
  • Net income in USD-293.70m
  • Incorporated2019
  • Employees108.00
  • Location
    Neumora Therapeutics Inc490 Arsenal Way, Suite 200WATERTOWN 02472United StatesUSA
  • Phone+1 (857) 760-0900
  • Fax+1 (302) 655-5049
  • Websitehttps://neumoratx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Spyre Therapeutics Inc0.00-214.90m1.39bn60.00--8.09-----7.44-7.440.006.370.00----0.00-68.40-101.87-81.72-118.83-------2,949.59----0.00---61.96-25.61-304.21------
Bicycle Therapeutics PLC (ADR)36.90m-166.28m1.40bn284.00--1.68--37.91-3.28-3.280.716312.040.0451--0.9806129,922.50-20.33-29.45-22.03-32.98-----450.64-571.36----0.0002--86.5230.47-60.28--19.82--
Intellia Therapeutics Inc43.09m-522.28m1.40bn526.00--1.46--32.53-5.45-5.450.45099.460.0357--5.6281,912.55-43.22-31.34-47.07-34.53-----1,212.19-654.71----0.00---30.403.57-1.48--17.08--
Cassava Sciences Inc0.00-17.66m1.54bn29.00--9.26-----0.3772-0.37720.003.470.00----0.00-8.91-30.74-10.98-32.12------------0.00-------27.50------
Neumora Therapeutics Inc0.00-293.70m1.55bn108.00--4.85-----1.77-1.770.002.000.00----0.00-65.46---70.23--------------0.00-------80.23------
BioCryst Pharmaceuticals Inc412.58m-123.82m1.55bn536.00------3.76-0.6073-0.60732.01-2.260.81360.42976.54769,736.90-24.42-47.95-32.17-64.8998.0697.06-30.01-114.942.73-0.4882.29--22.3774.218.33--42.73--
Viridian Therapeutics Inc302.00k-257.08m1.55bn96.00--3.00--5,146.21-4.31-4.310.0058.940.0006--5.213,212.77-46.71-55.59-49.63-60.32-----85,127.15-5,678.12----0.0282---82.28-48.16-83.05--15.08--
Travere Therapeutics Inc203.45m-348.96m1.57bn380.00------7.69-4.52-4.562.63-0.39090.30430.719210.24535,386.80-52.19-36.95-69.25-44.7795.2195.92-171.52-165.791.68--1.09--32.69-2.43-13.54--16.49--
Nurix Therapeutics Inc56.42m-176.98m1.58bn284.00--3.98--28.08-2.91-2.910.92225.620.1373----198,676.10-43.07-33.01-52.51-39.66-----313.65-260.65----0.00--99.3115.5020.19--39.42--
Dynavax Technologies Corp260.81m20.48m1.62bn408.00101.252.3864.906.230.12210.12211.835.190.25630.804.36639,242.602.014.162.145.7182.8564.837.859.1912.34--0.2470.00-67.8695.19-102.18---23.03--
Recursion Pharmaceuticals Inc65.18m-377.75m1.65bn500.00--3.13--25.29-1.53-1.530.26311.830.096--24.06130,368.00-55.66---65.45--35.07---579.51------0.0519--11.88---36.99------
Xencor Inc85.16m-198.24m1.69bn280.00--2.33--19.80-3.20-3.201.3710.350.0967--2.61304,157.20-22.89-3.70-24.90-4.12-----236.81-15.92----0.0243--2.2832.90-128.50--18.36--
Structure Therapeutics Inc (ADR)0.00-110.55m1.72bn148.00--1.92-----2.21-2.210.0015.660.00----0.00-19.23---20.17--------------0.00-------69.62------
Arvinas Inc161.10m-308.60m1.73bn445.00--2.94--10.71-4.79-4.792.388.530.1448--14.01362,022.50-27.73-22.01-37.81-26.47-----191.56-316.55----0.001---40.2640.53-30.02--0.4852--
Data as of Nov 22 2024. Currency figures normalised to Neumora Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

21.32%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20245.64m3.53%
T. Rowe Price Investment Management, Inc.as of 30 Sep 20245.23m3.27%
MIC Capital Management UK LLPas of 30 Sep 20244.46m2.79%
The Vanguard Group, Inc.as of 30 Sep 20244.21m2.63%
Fidelity Management & Research Co. LLCas of 30 Sep 20243.53m2.21%
ICONIQ Capital LLCas of 30 Sep 20243.40m2.12%
EcoR1 Capital, LLCas of 30 Sep 20242.07m1.29%
Geode Capital Management LLCas of 30 Sep 20241.98m1.24%
Avidity Partners Management LPas of 30 Sep 20241.80m1.13%
SSgA Funds Management, Inc.as of 30 Sep 20241.79m1.12%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.